High sensitive CRP is used as a marker of systemic inflammation in pulmonary disease. Results have shown an anti-inflammatory effect of atorvastatin in cardiopulmonary disease. Thus, this study was undertaken to assess the effect of atorvastatin on serum hs-CRP in chemical warfare victims. We studied 50 patients with mustard lung injury and high serum level of hs-CRP in a double blind, prospective study from Feb., 2011 to Dec., 2011 in Emam Khomeini Hospital, Ardabil, IRAN. Chemical warfare victims with pulmonary disease, who fulfilled entry criteria, were invited to participate in this study. Demographic data (height, weight, body mass index, blood pressure, drug history), COPD assessment test and St. George respiratory questionnaire are completed by patients. Then, pulseoximetry, spirometry and 6 minute walk distance tests are administered. Blood sample is drawn for serum hs-CRP level analysis. Coded pockets (from 1 to 50) containing atorvastatin and placebo (A or B codes) are randomly assigned by a nurse to the patients and the control groups (double blind). 40 mg atorvastatin tablets and the placebo are prescribed once daily for 9 weeks. After 4 weeks of intervention complete examination, pulseoximetry, spirometry and drug side effects are conducted by physician. At the end of the 9th weeks, physical examination, spirometry, pulseoximetry, St. George respiratory questionnaire, 6 minute walk distance test and blood sampling for hs-CRP will be conducted. It should be mentioned that, the patients are informed about the study and in the case of full written consult they are entered in the study.